Syngle’s 26F1 evaluated in Hirosaki University MSA model
March 4, 2021 Syngle Therapeutics and Hirosaki University announce their collaboration to evaluate Syngle’s anti-alphasynuclein antibody 26F1 in the adult onset Multiple System Atrophy (MSA) animal model developed by the Department of Neuropathology at Hirosaki University Graduate School of Medicine. The 26F1 antibody has been developed with support by the Michael J. Fox Foundation (Grant 11877).
Read more “Syngle’s 26F1 evaluated in Hirosaki University MSA model”